$295.00
-1.5%Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Healthy operating margins demonstrate effective cost control and strong business fundamentals.
Strong net margins indicate efficient operations and favorable tax/interest management.
Higher tax burden may reflect limited tax optimization or operations in high-tax jurisdictions.
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
SYK โข NYSE
| Stryker Corporation Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
25.1B | 22.6B | 20.5B | 18.4B | 17.1B | 14.4B | 14.9B | 13.6B | 12.4B | 11.3B | 9.9B | 9.7B | 9B | 8.7B | 8.3B | 7.3B | 6.7B | 6.7B | 6B | 5.4B | |
GROSS PROFIT | ||||||||||||||||||||
(9.1B) | (8.6B) | (8B) | (7.4B) | (6.4B) | (5.6B) | (5.5B) | (5B) | (4.5B) | (4.1B) | (3.6B) | (3.5B) | (3.1B) | (2.9B) | (2.8B) | (2.3B) | (2.2B) | (2.2B) | (1.9B) | (1.9B) | |
16.1B | 14B | 12.5B | 11B | 10.7B | 8.8B | 9.4B | 8.6B | 7.9B | 7.2B | 6.4B | 6.2B | 5.9B | 5.8B | 5.5B | 5B | 4.5B | 4.5B | 4.1B | 3.5B | |
OPERATING INCOME | ||||||||||||||||||||
(11.2B) | (8.9B) | (8.2B) | (7.3B) | (6.9B) | (5.7B) | (6B) | (5.5B) | (5.1B) | (4.7B) | (4.1B) | (4B) | (3.8B) | (3.9B) | (3.5B) | (3.1B) | (2.8B) | (3B) | (2.8B) | (2.4B) | |
(8.7B) | (7.5B) | (6.9B) | (6.1B) | (5.8B) | (4.8B) | (5B) | (4.6B) | (4.3B) | (4B) | (3.5B) | (3.4B) | (3.3B) | (3.4B) | (3.1B) | (2.7B) | (2.4B) | (2.6B) | (2.4B) | (2.1B) | |
(1.6B) | (1.4B) | (1.3B) | (1.2B) | (1.1B) | (905M) | (971M) | (862M) | (787M) | (715M) | (625M) | (614M) | (536M) | (471M) | (462M) | (393.9M) | (336.2M) | (367.8M) | (375.3M) | (324.6M) | |
4.9B | 5.1B | 4.3B | 3.7B | 3.8B | 3B | 3.4B | 3.1B | 2.8B | 2.6B | 2.3B | 2.2B | 2.1B | 1.9B | 2B | 1.9B | 1.7B | 1.6B | 1.3B | 1.1B | |
PRE-TAX INCOME | ||||||||||||||||||||
(607M) | (396M) | (356M) | (337M) | (337M) | (315M) | (287M) | (264M) | (247M) | (228M) | (108M) | (113M) | (95M) | (67M) | (94M) | (77.5M) | (14.5M) | (30.5M) | (22.2M) | (9.5M) | |
-486M | -257M | -281M | -243M | -269M | -213M | -132M | -145M | -187M | -199M | -94M | -85M | -71M | -20M | -24M | -28.8M | 39.4M | 67.2M | 63.3M | 31.9M | |
(902M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-375M | -1.6B | -608M | -1.1B | -1.5B | -1.1B | -826M | -748M | -704M | -656M | -517M | -1.1B | -887M | -212M | -285M | -121M | -100M | 26.3M | 43M | -23.2M | |
4.5B | 3.5B | 3.7B | 2.7B | 2.3B | 2B | 2.6B | 2.4B | 2.1B | 1.9B | 1.7B | 1.2B | 1.2B | 1.7B | 1.7B | 1.7B | 1.6B | 1.6B | 1.4B | 1.1B | |
NET INCOME | ||||||||||||||||||||
(1.3B) | (499M) | (508M) | (325M) | (287M) | (355M) | (479M) | -1.2B | (1B) | (274M) | (296M) | (645M) | (206M) | (407M) | (341M) | (456.2M) | (516.5M) | (432.4M) | (383.4M) | (326.1M) | |
3.2B | 3B | 3.2B | 2.4B | 2B | 1.6B | 2.1B | 3.6B | 1B | 1.6B | 1.4B | 515M | 1B | 1.3B | 1.3B | 1.3B | 1.1B | 1.1B | 1B | 777.7M |
SYK - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 20, 2026 | May 15, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 08, 2026 | May 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
8-K/A 8-K/A 2026 (Amended) N/A | April 09, 2026 | March 11, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 23, 2026 | May 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 23, 2026 | March 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 11, 2026 | March 11, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 11, 2026 | December 31, 2025 | 2025 |
Continue your SYK research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.